Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms

Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms

Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where “best-case” scenario has long been inadequate. This pro...

Full description

Bibliographic Details
Main Authors: Megan B. Barnet, Wendy A. Cooper, Michael J. Boyer, Steven Kao
Format: Article
Language:English
Published: MDPI AG 2018-06-01
Series:Journal of Clinical Medicine
Subjects:
non-small cell lung cancer
immunotherapy
checkpoint inhibitors
Online Access:http://www.mdpi.com/2077-0383/7/6/151

Internet

http://www.mdpi.com/2077-0383/7/6/151

Similar Items